drugset
drugset / Trial / NCT07481058

KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer

NCT07481058 ↗

Phase 2 Recruiting 60 enrolled Beijing Konruns Pharmaceutical Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of KC1036 in combination with PD-1 antibody and platinum-based chemotherapy as a first-line treatment for patients with unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC).

Timeline

Start
2025-12-12
Primary completion
2027-12
Completion
2028-12

Drugs

EvaluationDrugModalityDoseRoute
Subject KC1036 Unknown 20 mg Oral
Subject KC1036 Unknown 30 mg Oral
Subject KC1036 Unknown 40 mg Oral
Background Cisplatin Other / unclassified 60 mg/m2 Intravenous
Background Cisplatin Other / unclassified 75 mg/m2 Intravenous
Background Paclitaxel Small molecule 175 mg/m2 Intravenous
Background Toripalimab Monoclonal antibody 240 mg Intravenous

Indications

esophageal squamous cell carcinoma